当前位置: 首页 >> 检索结果
302. A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis.
作者: Daniel Blockmans.;Sara K Penn.;Arathi R Setty.;Wolfgang A Schmidt.;Andrea Rubbert-Roth.;Ellen M Hauge.;Helen I Keen.;Tomonori Ishii.;Nader Khalidi.;Christian Dejaco.;Maria C Cid.;Bernhard Hellmich.;Meng Liu.;Weihan Zhao.;Ivan Lagunes.;Ana B Romero.;Peter K Wung.;Peter A Merkel.; .
来源: N Engl J Med. 2025年392卷20期2013-2024页
Giant-cell arteritis is a systemic vasculitis with limited treatment options. The efficacy and safety of upadacitinib - a selective Janus kinase (JAK) inhibitor that blocks the signaling of several cytokines, including interleukin-6 and interferon-γ - are unknown in patients with giant-cell arteritis.
309. Modest Blood Pressure Increase with Age in Adults with Down's Syndrome.
作者: Andrea Kelly.;Meghan Shirley Bezerra.;Kate Fitzpatrick.;Kat Adams.;Ahtish Arputhan.;Rachel Walega.;Patricia Y Chu.;John Cockcroft.;Raymond R Townsend.
来源: N Engl J Med. 2025年392卷13期1346-1348页 314. Association between Wealth and Mortality in the United States and Europe.
作者: Sara Machado.;Ilias Kyriopoulos.;E John Orav.;Irene Papanicolas.
来源: N Engl J Med. 2025年392卷13期1310-1319页
Amid growing wealth disparity, we have little information on how health among older Americans compares with that among older Europeans across the distribution of wealth.
315. The Genetic Architecture of Congenital Diarrhea and Enteropathy.
作者: Zeenat Gaibee.;Neil Warner.;Katlynn Bugda Gwilt.;Wenjuan Li.;Rei Guan.;Michael Yourshaw.;Ryder Whittaker Hawkins.;Christiane Zorbas.;Jonathan St-Germain.;Mahdi Tabatabaie.;Suli Mao.;Vered Pinsk.;Baruch Yerushalmi.;Lee-Kai Wang.;Stanley F Nelson.;Laura Wozniak.;Dror S Shouval.;Manar Matar.;Amit Assa.;Nathaniel Frost.;Lissette Jimenez.;Sari Acra.;Thomas Walters.;Stephen Mouat.;Michael Li.;Denis L J Lafontaine.;Matthew Tyska.;Brian Raught.;Yaron Avitzur.;Wayne I Lencer.;James R Goldenring.;Martín G Martín.;Jay R Thiagarajah.;Aleixo M Muise.
来源: N Engl J Med. 2025年392卷13期1297-1309页
Next-generation sequencing has enabled precision therapeutic approaches that have improved the lives of children with rare diseases. Congenital diarrhea and enteropathies (CODEs) are associated with high morbidity and mortality. Although treatment of these disorders is largely supportive, emerging targeted therapies based on genetic diagnoses include specific diets, pharmacologic treatments, and surgical interventions.
316. Alteplase for Posterior Circulation Ischemic Stroke at 4.5 to 24 Hours.
作者: Shenqiang Yan.;Ying Zhou.;Maarten G Lansberg.;David S Liebeskind.;Changzheng Yuan.;Han Yu.;Fujian Chen.;Hongfang Chen.;Bing Zhang.;Lingqun Mao.;Xiaoling Zhang.;Xiaona Wang.;Xuting Zhang.;Yi Chen.;Huan Zhou.;Wansi Zhong.;Yaode He.;Kun Chen.;Jianbing Wang.;Hui Chen.;Yuhui Huang.;Bruce C V Campbell.;Min Lou.; .
来源: N Engl J Med. 2025年392卷13期1288-1296页
The effects and risks of the use of intravenous thrombolysis between 4.5 and 24 hours after the onset of a posterior circulation ischemic stroke are not well studied.
317. Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death.
作者: Marc Humbert.;Vallerie V McLaughlin.;David B Badesch.;H Ardeschir Ghofrani.;J Simon R Gibbs.;Mardi Gomberg-Maitland.;Ioana R Preston.;Rogerio Souza.;Aaron B Waxman.;Victor M Moles.;Laurent Savale.;Carmine Dario Vizza.;Stephan Rosenkranz.;Yaru Shi.;Barry Miller.;Harald S Mackenzie.;Samuel S Kim.;Maria José Loureiro.;Mahesh J Patel.;Joerg Koglin.;Alexandra G Cornell.;Marius M Hoeper.; .
来源: N Engl J Med. 2025年392卷20期1987-2000页
Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) functional class II or III pulmonary arterial hypertension. The effects of add-on sotatercept in patients with advanced pulmonary arterial hypertension and a high risk of death are unclear.
318. Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation.
作者: Tobias Reichlin.;Thomas Kueffer.;Patrick Badertscher.;Peter Jüni.;Sven Knecht.;Gregor Thalmann.;Nikola Kozhuharov.;Philipp Krisai.;Corinne Jufer.;Jens Maurhofer.;Dik Heg.;Tiago V Pereira.;Felix Mahfoud.;Helge Servatius.;Hildegard Tanner.;Michael Kühne.;Laurent Roten.;Christian Sticherling.; .
来源: N Engl J Med. 2025年392卷15期1497-1507页
Pulmonary-vein isolation is an effective treatment for paroxysmal atrial fibrillation. Pulsed field ablation (PFA) is a nonthermal ablation method with few adverse effects beyond the myocardium. Data are lacking on outcomes after PFA as compared with cryoballoon ablation as assessed with continuous rhythm monitoring.
319. Routine Cerebral Embolic Protection during Transcatheter Aortic-Valve Implantation.
作者: Rajesh K Kharbanda.;James Kennedy.;Zahra Jamal.;Matthew Dodd.;Richard Evans.;Kiran K Bal.;Alexander D Perkins.;Daniel J Blackman.;David Hildick-Smith.;Adrian P Banning.;Andreas Baumbach.;Peter Ludman.;Stephen Palmer.;Rodney H Stables.;Robert Henderson.;Clare Appleby.;James Cotton.;Nick Curzen.;Muhiddin Ozkor.;Jonathan Byrne.;Rajesh Aggarwal.;Rajiv Das.;Sagar Doshi.;Stuart Watkins.;Douglas F Muir.;Richard Anderson.;Saqib Chowdhary.;Richard Varcoe.;Stephen Dorman.;Sam Firoozi.;Raj Chelliah.;Colum Owens.;Simon Redwood.;Bernard Prendergast.;Javaid Iqbal.;Karim Ratib.;Ciprian Dospinescu.;Venkatesan Suresh.;Nicholas Cruden.;Thirumaran Rajathurai.;Iqbal S Malik.;Andrew Wiper.;Charis Costopoulos.;Ayush Khurana.;Amerjeet Banning.;Tim Clayton.; .
来源: N Engl J Med. 2025年
Transcatheter aortic-valve implantation (TAVI) is associated with procedure-related stroke. Cerebral embolic protection (CEP) devices may reduce embolization to the cerebral circulation and hence the incidence of stroke.
|